Nasopharyngeal Carcinoma

NPC Basics - Epstein's Evil Empire

Nasopharyngeal Carcinoma (NPC): Malignant epithelial tumor of the nasopharynx.

• Location: Predominantly Fossa of Rosenmüller (pharyngeal recess).
• Incidence: Bimodal peak age (e.g., 15-25 & 50-60 yrs).
• Geography: Endemic in S. China, SE Asia, N. Africa.
• Etiology - "Epstein's Evil Empire" Factors:
  • Epstein-Barr Virus (EBV): Strong causal link.
  • Genetic Susceptibility: HLA haplotypes (e.g., HLA-A2).
  • Environmental: Dietary nitrosamines (salted fish), poor ventilation. 📌 E.G.N. (EBV, Genetics, Nitrosamines).

⭐ EBV DNA load and IgA anti-VCA are crucial serological markers for NPC screening, diagnosis, and monitoring.

Pathology & Types - Cancer's Camouflage

WHO Classification is key:

⭐ Undifferentiated non-keratinizing carcinoma (WHO Type IIb or III in older classifications) is the most common type in endemic regions and has the strongest EBV association.

Clinical Clues - Silent Signs Shout

• Neck Mass (Most Common: ~75%):
  • Painless, firm cervical lymphadenopathy.
  • Often bilateral; Levels II, V most common.

  ⭐ Painless, firm neck mass is the most common initial symptom of NPC.

• Nasal Symptoms:
  • Unilateral nasal obstruction.
  • Epistaxis, blood-tinged discharge.
• Otological Symptoms (Eustachian Tube Dysfunction):
  • Serous otitis media (glue ear).
  • Unilateral hearing loss, tinnitus.
• Neurological Symptoms (Cranial Nerve Palsies):
  • CN V (Trigeminal): Facial pain/numbness.
  • CN VI (Abducens): Diplopia (most common CN involved).
  • Others: III, IV, IX, X, XI, XII.
  • 📌 Trotter's Syndrome Triad: Unilateral conductive deafness, trigeminal neuralgia (V), palatal immobility.
• Distant Metastasis:
  • Bone, lung, liver.

Detective Work - Unmasking the Culprit

• Initial Steps: History, clinical exam (posterior rhinoscopy/nasal endoscopy).
• Gold Standard: Endoscopic biopsy from Fossa of Rosenmüller (histopathology).

• Imaging Modalities:
  • MRI: Best for primary tumor, skull base, intracranial spread.
  • CT: Bony erosion, cervical nodes.
  • PET-CT: Staging, distant metastasis.

⭐ MRI is superior to CT for assessing primary tumor extent and intracranial spread in NPC.

• EBV Serology:

  • Markers: IgA anti-VCA, IgA anti-EA, EBV DNA.
  • Utility: Screening, prognosis, monitoring.

• Staging (AJCC 8th Ed.):

  • T: T1 (nasopharynx) → T4 (intracranial/CN).
  • N: N1 (unilat. ≤6cm) → N3 (>6cm/supraclav.).
  • M: M0 (no distant) vs. M1 (distant).

Treatment & Prognosis - Radiation's Resolve

• Mainstay: Radiotherapy (RT, ~70 Gy), IMRT preferred for primary & neck.

  ⭐ Radiotherapy is primary for NPC due to its anatomical location and radiosensitivity.

• Chemo (CT): Concurrent (CCRT) with Cisplatin for Stages II-IVB. Adjuvant/Neoadjuvant CT considered.
• Surgery: Limited role; mainly for recurrence or post-RT persistent neck nodes.
• Prognosis: Stage, WHO type, EBV DNA. 5-yr survival: Stage I >80%, Stage IV <40%.
• RT Complications: Xerostomia, mucositis, hearing loss, trismus.

High‑Yield Points - ⚡ Biggest Takeaways

• Strongly associated with Epstein-Barr Virus (EBV) infection, particularly endemic in Southern China & Southeast Asia.
• Most common presentation: painless cervical lymphadenopathy (neck mass); often bilateral.
• Unilateral serous otitis media in an adult is highly suspicious for NPC until proven otherwise.
• WHO Type III (undifferentiated carcinoma) is the most common histological type and most radiosensitive.
• Radiotherapy (± chemotherapy) is the primary treatment modality due to anatomical location and radiosensitivity.
• Fossa of Rosenmüller is the most common site of origin within the nasopharynx.
• Cranial nerve palsies (especially CN V & VI) can occur with skull base invasion (Trotter's syndrome).